Gush Etzion, Israel

Shlomo Seidman


Average Co-Inventor Count = 3.6

ph-index = 2

Forward Citations = 6(Granted Patents)


Location History:

  • Neve Daniel, IL (2000)
  • Gush Etzion, IL (2000 - 2006)

Company Filing History:


Years Active: 2000-2006

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Shlomo Seidman: Innovator in Central Nervous System Research

Introduction

Shlomo Seidman is a prominent inventor based in Gush Etzion, Israel. He has made significant contributions to the field of neuroscience, particularly in the diagnosis and treatment of central nervous system (CNS) conditions. With a total of 4 patents to his name, Seidman's work is paving the way for advancements in medical science.

Latest Patents

Seidman's latest patents focus on innovative uses of antibodies and methods for treating CNS injuries. One of his notable inventions involves antibodies that recognize acetylcholinesterase (AChE) or a C-terminal peptide derived from AChE. This invention is useful in diagnosing CNS stress, elevated glucocorticoid levels, disruption of the blood-brain barrier, and Alzheimer's disease. Additionally, he has developed methods and pharmaceutical compositions for treating CNS injuries. This method includes administering a therapeutically effective amount of an inhibitor of AChE production immediately following an injury, which can be a head injury, brain injury, or spinal cord trauma.

Career Highlights

Seidman is associated with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. His work has been instrumental in advancing the understanding of CNS disorders and developing potential therapeutic strategies.

Collaborations

Seidman has collaborated with notable researchers in his field, including Hermona Soreq and Fritz Eckstein. Their combined expertise has contributed to the success of various research initiatives.

Conclusion

Shlomo Seidman's innovative research and patents are making a significant impact in the field of neuroscience. His contributions are essential for the development of new diagnostic and therapeutic approaches for CNS-related conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…